Table 1: Notable Influenza Pandemics
Table 2: Influenza Symptoms
Table 3: Seasonal Influenza Immunization Recommendation Agencies by Country, 2016
Table 4: Immunization Recommendations and Most Frequently Administered Seasonal Influenza Vaccines, 2016
Table 5: Country Profile – France
Table 6: Country Profile – Germany
Table 7: Country Profile – Italy
Table 8: Country Profile – Spain
Table 9: Country Profile – UK
Table 10: Leading Seasonal Influenza Vaccines, 2016
Table 11: Product Profile – Fluzone Quadrivalent
Table 12: Immunogenicity Profile of Fluzone Quadrivalent
Table 13: Local and Systemic AEs of Fluzone Quadrivalent
Table 14: Fluzone Quadrivalent SWOT Analysis, 2016
Table 15: Global Sales Forecast ($m) for Fluzone Quadrivalent, 2015–2025
Table 16: Product Profile – Fluzone High-Dose
Table 17: Immunogenicity of Fluzone High-Dose Compared with Fluzone
Table 18: Local and Systemic AEs of Fluzone High-Dose
Table 19: Fluzone High-Dose SWOT Analysis, 2016
Table 20: Global Sales Forecast ($m) for Fluzone High-Dose, 2015–2025
Table 21: Product Profile – Fluzone Intradermal
Table 22: Comparison of Fluzone Intradermal Quadrivalent Versus Fluzone Intradermal Trivalent
Table 23: Local andsystemic AEs of Fluzone Intradermal Quadrivalent
Table 24: Fluzone Intradermal Quadrivalent SWOT Analysis, 2016
Table 25: Global Sales Forecast ($m) for Fluzone/Intanza Intradermal, 2015–2025
Table 26: Product Profile – Vaxigrip
Table 27: Cumulative Incidence of Influenza Infection in Children
Table 28: Local and Systemic AEs of Vaxigrip
Table 29: Vaxigrip SWOT Analysis, 2016
Table 30: Global Sales Forecast ($m) for Vaxigrip, 2015–2025
Table 31: Product Profile – Fluarix Tetra
Table 32: Immunogenicity Profile of Fluarix Tetra
Table 33: Local and Systemic AEs of Fluarix Tetra
Table 34: Fluarix Tetra SWOT Analysis, 2016
Table 35: Global Sales Forecast ($m) for Fluarix Tetra, 2015–2025
Table 36: Product Profile – Fluvirin
Table 37: Immunogenicity of Fluvirin in Adults
Table 38: Local and Systemic AEs of Fluvirin
Table 39: Fluvirin SWOT Analysis, 2016
Table 40: Global Sales Forecast ($m) for Fluvirin, 2015–2025
Table 41: Product Profile – Afluria
Table 42: Immunogenicity of Afluria in Adults
Table 43: Local and Systemic AEs of Afluria
Table 44: Afluria SWOT Analysis, 2016
Table 45: Global Sales Forecast ($m) for Afluria, 2015–2025
Table 46: Product Profile – Agrippal
Table 47: Immunogenicity of Agrippal
Table 48: Local and Systemic AEs of Agrippal
Table 49: Agrippal SWOT Analysis, 2016
Table 50: Global Sales Forecast ($m) for Agrippal, 2015–2025
Table 51: Product Profile – Fluad
Table 52: Immunogenicity Comparison of Fluad Versus Agriflu
Table 53: Local and Systemic AEs of Fluad
Table 54: Fluad SWOT Analysis, 2016
Table 55: Global Sales Forecast ($m) for Fluad, 2015–2025
Table 56: Product Profile – FluMist Quadrivalent
Table 57: Noninferiority of FluMist Quadrivalent Compared with FluMist Trivalent
Table 58: AEs of FluMist Quadrivalent
Table 59: FluMist Quadrivalent SWOT Analysis, 2016
Table 60: Global Sales Forecast ($m) for FluMist Quadrivalent, 2015–2025
Table 61: Product Profile – Flublok
Table 62: Immunogenicity of Flublok compared with Fluzone and Fluzone High-Dose
Table 63: Local and Systemic AEs of Flublok
Table 64: Flublok SWOT Analysis, 2016
Table 65: Global Sales Forecast ($m) for Flublok, 2015–2025
Table 66: Product Profile – Flucelvax
Table 67: Immunogenicity of Flucelvax
Table 68: Local and Systemic AEs of Flucelvax
Table 69:Flucelvax SWOT Analysis, 2016
Table 70: Global Sales Forecast ($m) for Flucelvax, 2015–2025
Table 71: Summary of Other Marketed Seasonal Influenza Vaccines, 2016
Table 72: Unmet Need and Opportunity in Seasonal Influenza Vaccines, 2016
Table 73: Seasonal Influenza Vaccines – Late-Stage Pipeline, 2016
Table 74: Quadrivalent Versions of Marketed Vaccines
Table 75: Product Profile – Seasonal Influenza VLP Vaccine
Table 76: Seasonal Influenza VLP Vaccine SWOT Analysis, 2016
Table 77: Global Sales Forecast ($m) for Seasonal Influenza VLP Vaccine, 2015–2025
Table 78: Product Profile – VN-100
Table 79: Comparison of Immunogenicity Profile of VN-100 and Subcutaneous Standard Vaccine
Table 80: Frequency of Local and Systemic AEs of VN-100 Compared with a Comparator Subcutaneous Vaccine
Table 81: VN-100 SWOT Analysis, 2016
Table 82: Global Sales Forecast ($m) for VN-100, 2015–2025
Table 83: Product Profile – Quadrivalent Seasonal Influenza VLP Vaccine
Table 84: Quadrivalent Seasonal Influenza VLP Vaccine SWOT Analysis, 2016
Table 85: Global Sales Forecast ($m) for Quadrivalent Seasonal Influenza VLP Vaccine, 2015–2025
Table 86: Promising Vaccines in Early-Stage Development, 2016
Table 87: Summary of Seasonal Influenza Vaccines in Development Outside the 7MM, 2016
Table 88: Sales Forecasts ($m) for Seasonal Influenza Vaccines in France, 2015 –2025
Table 89: Key Events Impacting Sales for Seasonal Influenza in France, 2015?2025
Table 90: France Seasonal Influenza Vaccines Market – Drivers and Barriers, 2015?2025
Table 91: Sales Forecasts ($m) for Seasonal Influenza Vaccines in Germany, 2015 –2025
Table 92: Key Events Impacting Sales for Seasonal Influenza in Germany, 2015?2025
Table 93: Germany Seasonal Influenza Vaccines Market – Drivers and Barriers, 2015?2025
Table 94: Sales Forecasts ($m) for Seasonal Influenza Vaccines in Italy, 2015–2025
Table 95: Key Events Impacting Sales for Seasonal Influenza in Italy, 2015?2025
Table 96: Italy Seasonal Influenza Vaccines Market – Drivers and Barriers, 2015?2025
Table 97: Sales Forecasts ($m) for Seasonal Influenza Vaccines in Spain, 2015 –2025
Table 98: Key Events Impacting Sales for Seasonal Influenza in Spain, 2015?2025
Table 99: Spain Seasonal Influenza Vaccines Market – Drivers and Barriers, 2015?2025
Table 100: Sales Forecasts ($m) for Seasonal Influenza Vaccines in the UK, 2015–2025
Table 101: Key Events Impacting Sales for Seasonal Influenza in the UK, 2015?2025
Table 102: UK Seasonal Influenza Vaccines Market – Drivers and Barriers, 2015?2025
Table 103: Key Launch Dates
Table 104: High-Prescribing Physicians (non-KOLs) Surveyed, By Country